In Action

The AMR Industry Alliance members have a wide range of expertise and work in many different environments. As a result the way they contribution to tackling AMR varies. The case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps they are taking to invest in new research to develop new antibiotics and vaccines, and prevent infection and improve appropriate use of antibiotics! We hope that others can draw on the Alliance members’ successes and failures, and be inspired to also take actions to address AMR.

We measure and drive the life-sciences industry progress to curb antimicrobial resistance
in four different areas:

research & science

Invest in R&D to meet public health needs with new innovative diagnostics and treatments

appropriate use

Work to reduce the development of antimicrobial resistance

access

Improve access to high-quality antibiotics and ensuring that new ones are available to all

environment

Reduce the environmental impact of manufacturing

Otsuka – FighTBack Initiative

Find out more

GSK – Appropriate Use Initiatives

Find out more

Mylan – Implementing ‘Zero Liquid Discharge’ at Manufacturing Facilities in India

Find out more

Aequor – ABD (Aequor Biofilm Dispersant) Effectively Combats AMR without Toxicity or Triggering Resistance

Find out more
Abbott (formerly Alere)

Abbott (formerly Alere) – Test Target Treat™

In order to preserve the antibiotics that are currently available we must promote the appropriate use of antibiotics....

Diagnostics
Appropriate Use
Achaogen Inc., United States

CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant

Drug-resistant infections are complex and developing new antibiotics challenging, timely and costly. But restoring the R&D pipeline is vital to address the seriously increasing threat of superbugs...

R&D Pharma
Research & Science
Aequor Inc., United States

Aequor – ABD (Aequor Biofilm Dispersant) Effectively Combats AMR without Toxicity or Triggering Resistance

Aequor's ABD (Aequor Biofilm Dispersant) represents a leap forward in the race between modern medicine and antimicrobial/drug-resistant (AMR) bacteria and fungi. The polymer-like structure of proteins...

Biotechs
Research & Science
AiCuris Anti-infective Cures GmbH, Germany

AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria

With the rapid emergence and spread of MDR bacterial infections, antimicrobial resistance (AMR) has become a major global public health threat. Patients in intensive care units (ICUs) are particularly...

Research & Science
Antabio, France

ANTABIO – PEi Program

Antimicrobial resistance affects a high percentage of patients suffering from cystic fibrosis. This happens due to a combination of a variety of factors, which includes physiological changes. Thus, in...

R&D Pharma
Research & Science
AstraZeneca plc, United Kingdom

AstraZeneca – Integrating human and environmental health in antibiotic risk assessment

Antibiotics are vital in the treatment of bacterial infectious diseases but when released into the environment they may impact non-target organisms that perform vital ecosystem services and enhance an...

R&D Pharma
Environment
BD, United States

BD – “Resistance Fighter” Awareness and Mobilization Campaign

This campaign addresses the need to raise global awareness about antimicrobial resistance (AMR) and the important roles that everyone plays in the fight against its spread. This campaign targets all w...

Diagnostics
Appropriate Use
BD, United States

BD – AMR Education and Training Collaboration with the London School of Hygiene and Tropical Medicine (LSHTM)

Need to build training programs and capacity building for continuous education to help raise awareness of AMR and improve diagnostic utilization....

Diagnostics
Appropriate Use
BD, United States

BD – Phoenix™ M50 System

Targeted antimicrobial therapy. Wrong diagnosis can lead to wrong therapies, which in turn delay treatment and can cause AMR...

Diagnostics
Appropriate Use
Research & Science
BEAM Alliance

BEAM Alliance – Guidelines as to how antibacterial R&D could be revived and proposes specific support for SME-driven innovation in the AMR field.

Due to their versatile properties, bacteria are evolving resistance faster than policymakers are implementing action. It is of enormous importance to ultimately revive R&D in AMR by developing com...

Biotechs
Research & Science
bioMérieux, France

bioMérieux – Collaborative project with Antwerp University (Pr Herman Goossens)

The importance of surveillance of antimicrobial use and resistance profiles has been clearly recognized in several reports, such as Lord Jim O’Neill’s report with a specific issue dedicated on sur...

Diagnostics
Appropriate Use
Research & Science
BioVersys AG, Switzerland

BioVersys

Tuberculosis (TB) is the world’s leading infectious disease killer. It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year—490,000 of TB cases are multid...

R&D Pharma
Research & Science
Cepheid, United States

Cepheid – Global Laboratory Initiative

WHO’s global strategy for tuberculosis (TB) prevention, care and control for 2015–2035 (known as the End TB Strategy) calls for the early diagnosis of TB and universal drug-susceptibility testing...

Diagnostics
Access
Combioxin SA

CAL02

Antibiotics, on their own, have failed to significantly decrease mortality rates and to provide a long-term solution against the rise of severe and resistant infections. Moreover, the increasing use o...

Biotechs
Research & Science
Da Volterra, France

Da Volterra – DAV132

The usage of large-spectrum antibiotics prescribed to treat infections, can generate consequences on patients health linked to the deleterious effects of those antibiotics on the microbiota. It is wel...

Biotechs
R&D Pharma
Research & Science
Destiny Pharma plc., United Kingdom (DEST.L)

Prevention of Post-Surgical Staphylococcal Infections.

Infection prevention initiatives based on widespread antibacterial drug use such as that advocated by recent 2016 WHO prevention of Surgical Site Infection guidelines are compromised by rapid...

Biotechs
R&D Pharma
Research & Science
DSM Sinochem Pharmaceuticals, Netherlands

DSM – Sustainably-produced Antibiotics

Common practice in today’s pharmaceutical manufacturing industry requires large volumes of chemical solvents, produces millions of tonnes of CO2 emissions, and could contribute to the growing threat...

Generics
Environment
GlaxoSmithKline plc, United Kingdom

GSK – Appropriate Use Initiatives

Antibiotics should only be used in patients who need them. Ensuring antibiotics are used appropriately is a key component of antimicrobial stewardship and GSK believes that industry should support con...

R&D Pharma
Appropriate Use
GlaxoSmithKline plc, United Kingdom

GSK – Improving Access to Antibiotics and Vaccines

GSK recognizes that access to medicines and healthcare should be available to everyone who needs them, no matter where they live or how much they can afford. In many countries, we still need to improv...

R&D Pharma
Access
GlaxoSmithKline plc, United Kingdom

GSK – Public-Private Partnerships to Share Knowledge and Expertise in R&D

Due to the complexities of researching new AMR-relevant products, it is important that the industry collaborates with other stakeholders to share knowledge and expertise. This can improve the efficien...

R&D Pharma
Research & Science
GlaxoSmithKline plc, United Kingdom

GSK – Responsible Antibiotic Manufacturing

GSK recognises that factory discharges of antibiotics and antimicrobial active materials could contribute to an increase in resistant genes in the environment. GSK is committed to ensuring that discha...

R&D Pharma
Environment
GlaxoSmithKline plc, United Kingdom

GSK – Sales Incentives Programme and Healthcare Provider Engagement Model

Antibiotics need to be conserved and used appropriately to minimise the development of resistance. Sales and marketing activity focused purely on driving volume of sales risks being counter to what is...

R&D Pharma
Appropriate Use
GlaxoSmithKline plc, United Kingdom

GSK – Survey of Antibiotic Resistance (SOAR)

Understanding local antibiotic drug resistance patterns helps encourage appropriate antibiotic usage; supports development of local antibiotic prescribing guidelines and vaccination strategies; and, m...

R&D Pharma
Appropriate Use
iNtRON Biotechnology, Inc., Korea

iNtRON- N-Rephasin® SAL200 (Tonabacase)

A novel approach and break-through in addressing the problem of antibiotic-resistant bacterial infections. The key features of SAL200 include rapid bacteriocidal activity, antibacterial activity again...

R&D Pharma
Research & Science
Johnson & Johnson, United States

Johnson & Johnson – Access to diagnostics and therapeutic solutions for TB and MDR-TB (with FIND Diagnostics)

While MDR-TB is threatening the global effort to eliminate TB, the high rates of missed or delayed diagnosis are preventing prompt, effective treatment and allowing MDR-TB’s continued spread. The ne...

R&D Pharma
Access
Appropriate Use
Johnson & Johnson, United States

SIRTURO® (bedaquiline) Development and Launch

Globally, more people die of tuberculosis than any other infectious disease. Drug resistant tuberculosis (MDR-TB) accounts for roughly one-third of all AMR fatalities. Each year, roughly 500,000 peopl...

Biotechs
R&D Pharma
Access
Appropriate Use
Environment
Research & Science
Merck & Co., Inc., Kenilworth, New Jersey, United States

Leveraging global surveillance data to develop rapid diagnostics: MSD & OpGen’s Collaboration

Rapid diagnostics for pathogen identification and antibiotic susceptibility testing are central to developing global solutions for antimicrobial resistance. Diagnostics can help distinguish between in...

Diagnostics
R&D Pharma
Appropriate Use
Research & Science
Merck & Co., Inc., Kenilworth, New Jersey, United States

Merck & Co., Inc – Partnering with Local Hospitals Worldwide to Implement Antimicrobial Stewardship (AMS) Programs

Any use of antimicrobials contributes to the development of resistance, but widespread unnecessary and excessive use makes it worse. AMS refers to a collection of interventions geared toward optimizin...

R&D Pharma
Appropriate Use
Merck & Co., Inc., Kenilworth, New Jersey, United States

Merck & Co., Inc. – Study for Monitoring Antimicrobial Resistance Trends (SMART)

Surveillance studies can yield important information for identification of trends in pathogen incidence and AMR, and provide early indicators of the emergence of resistant strains. Such studies are fu...

R&D Pharma
Appropriate Use
Mylan, United States

Mylan – Implementing ‘Zero Liquid Discharge’ at Manufacturing Facilities in India

One main cause of the rise of AMR is the over-prescribing and inappropriate use of antibiotics in or by humans, as well as improper disposal. Another main cause is the use of antibiotics in intensive...

Generics
Environment
Novartis AG, Switzerland

Novartis – KAF156 Molecule

KAF156 was discovered and is being developed to address the lack of new molecules active against malaria parasites. Next-generation antimalarials are urgently needed to secure the gains made over the...

R&D Pharma
Research & Science
Otsuka, Japan

Otsuka – FighTBack Initiative

Considering the dramatic rise in bacterial resistance worldwide, rational use of the MDR-TB compound delamanid is critical to ensuring that the greatest number of patients have access to this medicine...

R&D Pharma
Access
Appropriate Use
Research & Science
Otsuka, Japan

Otsuka – MDR-Tuberculosis R&D

TB bacteria are so resilient that patients must take a regimen of several different medicines for anywhere from six months to a year. In the case of drug-resistant strains such as multidrug-resistant...

R&D Pharma
Research & Science
Peptilogics Inc., United States

Peptilogics – Innovative Peptide-Based Platform to Develop a New Class of Potent Antibiotics

Increasing numbers of U.S. cases of bacterial infections, particularly Gram negative infections in the hospital setting, are resistant to last-resort antibiotics. We are even seeing infections by bact...

Biotechs
Research & Science
Peptilogics Inc., United States

Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection

Prosthetic Joint Infection (PJI) is one of the most challenging complications of joint arthroplasty and a serious, life threatening condition with few effective treatment options. “Total joint re...

Biotechs
Research & Science
Pfizer Inc., United States

Pfizer – Antimicrobial Access Programs

At Pfizer we believe that access to quality healthcare and the opportunity to lead healthy lives is an extremely important social goal. The power and value of collaboration between public and private...

R&D Pharma
Access
Pfizer Inc., United States

Pfizer – Antimicrobial Innovative Vaccines

Pfizer has made significant and substantial investments in vaccine R&D to develop new vaccines and to support several vaccines already in clinical usage. It has been clearly demonstrated that bact...

R&D Pharma
Research & Science
Pfizer Inc., United States

Pfizer – Antimicrobial Testing Leadership and Surveillance (ATLAS)

In the fight against the rise of antimicrobial resistance, it is important to stay abreast of trends in antibiotic resistance as they emerge. But while the US and Europe have public healthcare organiz...

Biotechs
Diagnostics
Generics
R&D Pharma
Appropriate Use
Research & Science
Pfizer Inc., United States

Pfizer – Massive Open Online Course on Stewardship

Pfizer routinely sponsors and conducts medical education outreach to healthcare providers through a variety of mechanisms, including medical symposia and Pfizer sponsored preceptorships, to ensure app...

R&D Pharma
Appropriate Use
Pfizer Inc., United States

Pfizer, ICMR to Establish a Centre in New Delhi to Combat AMR

The project will help address the growing threat of antimicrobial resistance (AMR) in India, as it is important to invest all the necessary resources in combating the adverse impact of AMR, due to the...

R&D Pharma
Appropriate Use
Research & Science
Qiagen, Germany

Qiagen – Detection and Surveillance of Antibiotic Resistance Genes From Food and Fertilizer Sources Using qPCR Technology

One potential way to acquire antibiotic resistance genes is through the food supply chain. Both livestock and feed may acquire antibiotic resistant bacteria via different mechanisms. Foodstuffs can be...

Diagnostics
Research & Science
Sanofi S.A., France

BACT’ATTACK®

By 2050, if considerable gains are not made to combat AMR, it could become the main cause of death among all diseases worldwide. In addition to promoting and fostering R&D for AMR-related health p...

R&D Pharma
Appropriate Use
Shionogi & Co. Ltd., Japan

Shionogi – Antimicrobial Stewardship Program

At Shionogi, antimicrobial stewardship means selecting the best medicine and administration method and ensuring treatment starts and ends at the optimal time, in order to make treatment safe and relia...

R&D Pharma
Appropriate Use

stay informed

Subscribe to receive our updates

  • I consent to the storage of my data according to the Privacy Policy